
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapeutics in the areas of immunology, inflammation, and oncology. Its positive outlook is based on a strong regulatory strategy and a fully funded path to approval and launch in 2027, supported by a strong management team with a plan for a potential September 2026 NDA submission. However, the company's liquidity remains constrained despite a recent exchange offer, and its success will depend on constructive feedback from the FDA on its NDA and the removal of its significant near-term maturity wall.
Bears say
Gossamer Bio is facing several challenges that could hinder its success in the clinical-stage biopharmaceutical industry, including a high-risk niche focus that may limit its commercial opportunity, potential anti-fibrotic activity that has not yet been fully validated, and a cost-cutting measure that may impact the company's ability to advance its pipeline products. Additionally, while the company's data may provide biological coherence and strengthen its pharmacodynamic narrative, it does not fully de-risk its potential opportunities without clinical data. Furthermore, although management has indicated that the upcoming FDA meeting may be pivotal for the company, there is still uncertainty around the site exclusion issue and the potential impact it may have on the company's data.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares